Mineralys Therapeutics, Inc.
MLYS
$25.02
-$0.71-2.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.01% | 54.55% | 54.92% | 58.57% | 66.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.33% | 9.35% | 50.96% | 91.75% | 127.27% |
| Operating Income | 11.33% | -9.35% | -50.96% | -91.75% | -127.27% |
| Income Before Tax | 13.02% | -11.82% | -59.41% | -107.62% | -147.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.02% | -11.82% | -59.41% | -107.62% | -147.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.02% | -11.82% | -59.41% | -107.62% | -147.31% |
| EBIT | 11.33% | -9.35% | -50.96% | -91.75% | -127.27% |
| EBITDA | 11.34% | -30.88% | -152.14% | -469.77% | -- |
| EPS Basic | 34.71% | 9.59% | -31.53% | -70.94% | -82.83% |
| Normalized Basic EPS | 34.72% | 9.60% | -31.53% | -70.93% | -82.83% |
| EPS Diluted | 34.71% | 9.59% | -31.53% | -70.94% | -82.83% |
| Normalized Diluted EPS | 34.72% | 9.60% | -31.53% | -70.93% | -82.83% |
| Average Basic Shares Outstanding | 39.03% | 29.87% | 25.31% | 22.84% | 34.24% |
| Average Diluted Shares Outstanding | 39.03% | 29.87% | 25.31% | 22.84% | 34.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |